Jubilant Pharmova’s Spokane facility receives VAI classification from US FDA

The classification follows a June inspection, with the regulator indicating that the identified conditions do not warrant administrative or regulatory action.
Affected stocks
Neutral1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Jubilant Pharmova (JUBLPHARMA).
- Category: Company.
Why it matters
A routine update for Jubilant Pharmova. Use the price and stock snapshot to gauge how the market is responding.







